It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The HUSH complex represses retroviruses, transposons and genes to maintain the integrity of vertebrate genomes. HUSH regulates deposition of the epigenetic mark H3K9me3, but how its three core subunits — TASOR, MPP8 and Periphilin — contribute to assembly and targeting of the complex remains unknown. Here, we define the biochemical basis of HUSH assembly and find that its modular architecture resembles the yeast RNA-induced transcriptional silencing complex. TASOR, the central HUSH subunit, associates with RNA processing components. TASOR is required for H3K9me3 deposition over LINE-1 repeats and repetitive exons in transcribed genes. In the context of previous studies, this suggests that an RNA intermediate is important for HUSH activity. We dissect the TASOR and MPP8 domains necessary for transgene repression. Structure-function analyses reveal TASOR bears a catalytically-inactive PARP domain necessary for targeted H3K9me3 deposition. We conclude that TASOR is a multifunctional pseudo-PARP that directs HUSH assembly and epigenetic regulation of repetitive genomic targets.
The HUSH complex plays a key role in controlling transcription of viruses and transposable elements. Here, the authors define the biochemical basis of HUSH assembly and show that the TASOR subunit contains a pseudo-PARP domain critical for HUSH-dependent transgene repression and H3K9me3 deposition over targets genome wide.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Cambridge, MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Molecular Immunity Unit, Department of Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Lund University, Department of Experimental Medical Science, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
2 University of Cambridge School of Clinical Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); The Gurdon Institute, Cambridge, UK (GRID:grid.450000.1) (ISNI:0000 0004 0606 5024)
3 University of Cambridge School of Clinical Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
4 University of Cambridge School of Clinical Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Department of Pathology, University of Cambridge, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
5 University of Cambridge, MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Molecular Immunity Unit, Department of Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Lawrence Berkeley National Laboratory, Molecular Biophysics and Integrated Bioimaging Division, Berkeley, USA (GRID:grid.184769.5) (ISNI:0000 0001 2231 4551)
6 University of Cambridge, MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Molecular Immunity Unit, Department of Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge School of Clinical Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); MRC Laboratory of Molecular Biology, Cambridge, UK (GRID:grid.42475.30) (ISNI:0000 0004 0605 769X)
7 Structural Studies Division, MRC Laboratory of Molecular Biology, Cambridge, UK (GRID:grid.42475.30) (ISNI:0000 0004 0605 769X)
8 University of Cambridge, MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Molecular Immunity Unit, Department of Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge School of Clinical Medicine, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)